Cogent Biosciences (COGT) Equity Average (2018 - 2021)
Historic Equity Average for Cogent Biosciences (COGT) over the last 4 years, with Q3 2021 value amounting to $205.0 million.
- Cogent Biosciences' Equity Average rose 1408029.32% to $205.0 million in Q3 2021 from the same period last year, while for Sep 2021 it was $205.0 million, marking a year-over-year increase of 1408029.32%. This contributed to the annual value of $133.2 million for FY2020, which is 18960.93% up from last year.
- Latest data reveals that Cogent Biosciences reported Equity Average of $205.0 million as of Q3 2021, which was up 1408029.32% from $219.8 million recorded in Q2 2021.
- Cogent Biosciences' Equity Average's 5-year high stood at $230.7 million during Q1 2021, with a 5-year trough of -$55.1 million in Q1 2018.
- Over the past 4 years, Cogent Biosciences' median Equity Average value was $44.5 million (recorded in 2019), while the average stood at $70.9 million.
- Per our database at Business Quant, Cogent Biosciences' Equity Average crashed by 10428.92% in 2020 and then skyrocketed by 1408029.32% in 2021.
- Quarter analysis of 4 years shows Cogent Biosciences' Equity Average stood at $63.9 million in 2018, then crashed by 52.74% to $30.2 million in 2019, then skyrocketed by 251.9% to $106.2 million in 2020, then surged by 92.97% to $205.0 million in 2021.
- Its last three reported values are $205.0 million in Q3 2021, $219.8 million for Q2 2021, and $230.7 million during Q1 2021.